



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/001,848	11/20/2001	Stewart D. Chipman	3081-A	1953

22932 7590 05/21/2003

IMMUNEX CORPORATION
LAW DEPARTMENT
51 UNIVERSITY STREET
SEATTLE, WA 98101

EXAMINER

BELYAVSKYI, MICHAEL A

ART UNIT	PAPER NUMBER
----------	--------------

1644

DATE MAILED: 05/21/2003

6

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

10/001,848

Applicant(s)

CHIPMAN ET AL.

Examiner

Michail A Belyavskyi

Art Unit

1644

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on ____.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☐ Claim(s) 1-21 is/are pending in the application.
- 4a) Of the above claim(s) ____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) ____ is/are allowed.
- 6) ☐ Claim(s) ____ is/are rejected.
- 7) ☐ Claim(s) ____ is/are objected to.
- 8) ☒ Claim(s) 1-21 are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on ____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on ____ is: a) ☐ approved b) ☐ disapproved by the Examiner.
- If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. ____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.
- 14) ☒ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s) ____.
- 4) ☐ Interview Summary (PTO-413) Paper No(s). ____.
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: _____.

Art Unit: 1644

DETAILED ACTION

1. *Claims 1-21 are pending.*

Restriction Requirement

2. Restriction to one of the following inventions is required under 35 U.S.C. § 121:
 - I. Claims 1-6, drawn to a method of activating the immune system in a mammal comprising administering to the mammal an effective amount of an IMXP-888 polypeptide, wherein IMXP-888 polypeptide comprises an amino acid sequence of residues 18 to 375 of SEQ ID NO:3 or a polypeptide that is at least 80 % homologous to a polypeptide sequence that encodes residues 18 to 375 of SEQ ID NO:3 , classified in Class 424, subclass 184.1.
 - II. Claims 1-4 and 6, drawn to a method of activating the immune system in a mammal comprising administering to the mammal an effective amount of an IMXP-888 polypeptide, wherein IMXP-888 polypeptide comprises an amino acid sequence of residues 13 to 371 of SEQ ID NO:1 or a polypeptide that is at least 80 % homologous to a polypeptide sequence that encodes residues 13 to 371 of SEQ ID NO:1 , classified in Class 424, subclass 184.1.
 - III. Claims 1-4 and 6, drawn to a method of activating the immune system in a mammal comprising administering to the mammal an effective amount of an IMXP-888 polypeptide, wherein IMXP-888 polypeptide comprises an amino acid sequence of residues 13 to 280 of SEQ ID NO:2 or a polypeptide that is at least 80 % homologous to a polypeptide sequence that encodes residues 13 to 280 of SEQ ID NO:2 , classified in Class 424, subclass 184.1.
 - IV. Claims 1-8, drawn to a method of activating the immune system in a mammal comprising administering to the mammal an effective amount of IMXP-888 polypeptide fused to a heterologous polypeptide, wherein IMXP-888 polypeptide comprises an amino acid sequence of residues 18 to 375 of SEQ ID NO:3 or a polypeptide that is at least 80 % homologous to a polypeptide sequence that encodes residues 18 to 375 of SEQ ID NO:3 , classified in Class 424, subclass 192.1.

Art Unit: 1644

- V. Claims 1-4 and 6-8, drawn to a method of activating the immune system in a mammal comprising administering to the mammal an effective amount of an IMXP-888 polypeptide fused to a heterologous polypeptide, wherein IMXP-888 polypeptide comprises an amino acid sequence of residues 13 to 371 of SEQ ID NO:1 or a polypeptide that is at least 80 % homologous to a polypeptide sequence that encodes residues 13 to 371 of SEQ ID NO:1 , classified in Class 424, subclass 192.1
- VI. Claims 1-4 and 6-8, drawn to a method of activating the immune system in a mammal comprising administering to the mammal an effective amount of an IMXP-888 polypeptide fused to a heterologous polypeptide, wherein IMXP-888 polypeptide comprises an amino acid sequence of residues 13 to 280 of SEQ ID NO:2 or a polypeptide that is at least 80 % homologous to a polypeptide sequence that encodes residues 13 to 280 of SEQ ID NO:2 , classified in Class 424, subclass 192.1.
- VII. Claims 9 ,10 and 12 , drawn to a method of treating an inflammatory disorder in a mammal, comprising administering an effective amount of an IMXP-888 antagonist, wherein an IMXP-888 antagonist is an antibody, classified in Class 424, subclasses 130.1 and 139.1
- VIII. Claims 9 ,11 and 12 , drawn to a method of treating an inflammatory disorder in a mammal, comprising administering an effective amount of an IMXP-888 antagonist, wherein an IMXP-888 antagonist is a ribozyme, classified in Class 424, subclass 184.1
- IX. Claims 13-17, drawn to a method of using an IMXP-888 polypeptide to identify an IMXP-888 receptor, classified in Class 435, subclass 7.1.
- X. Claims 18 – 21, drawn to a method for identifying compound capable of enhancing or inhibiting a biological activity of an IMXP-888 polypeptide, classified in Class 435, subclass 7.1.

4. Groups I- X are different methods. These invention are different with respect to ingredients, method steps, and endpoints; therefore, each method is patentably distinct.

5. These inventions are distinct for the reasons given above. In addition, they have acquired a separate status in the art as shown by different classification and/or recognized divergent subject matter. Further, even though in some cases the classification is shared, a different field of search would be required based upon the structurally distinct products recited and the various methods of use comprising distinct method steps. Moreover, a prior art search also requires a literature search. It is an undue burden for the examiner to search more than one invention. Therefore restriction for examination purposes as indicated is proper.

Art Unit: 1644

Species Election

6. Applicant is further required under 35 USC 121 (1) to elect a single disclosed species to which the claims would be restricted if no generic claim is finally held to be allowable and (2) to list all claims readable thereon including those subsequently added.

A. If one of the Group I –VI is elected, applicant is required to elect a specific method of activating the immune system in a mammal, wherein a mammal has a condition selected from the group recited in claim 2.

These species are distinct because the specific a method of activating the immune system in a mammal, wherein a mammal has a condition selected from the group recited in claim 2 differ with respect to the specific condition; thus each specific method employing a specific condition represents patentably distinct subject matter that would require different searches in the scientific literature.

B. If Group IX is elected, applicant is required to elect a specific method of using an IMXP-888 polypeptide to identify an IMXP-888 receptor, wherein a specific hematopoietic cell is selected from the group recited in claim 15.

These species are distinct because the specific method of using an IMXP-888 polypeptide to identify an IMXP-888 receptor, wherein a specific hematopoietic cell is selected from the group recited in claim 15 differ with respect to the specific type of hematopoietic cell; thus each specific method employing a specific type of hematopoietic cell represents patentably distinct subject matter that would require different searches in the scientific literature.

7. Applicant is advised that a response to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 C.F.R. § 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. M.P.E.P. § 809.02(a).

Art Unit: 1644

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. § 103 of the other invention.


8. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 C.F.R. § 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently-filed petition under 37 C.F.R. § 1.48(b) and by the fee required under 37 C.F.R. § 1.17(h).

9. A telephone call was made to Kathleen Fowler on 05/09/03 to request an oral election to the above restriction requirement, but did not result in an election being made.

10. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michail Belyavskyi whose telephone number is (703) 308-4232. The examiner can normally be reached Monday through Friday from 9:00 AM to 5:30 PM. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (703) 308-3973. Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center 1600 receptionist whose telephone number is (703) 308-0196.

Papers related to this application may be submitted to Technology Center 1600 by facsimile transmission. Papers should be faxed to Technology Center 1600 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The CM1 Fax Center telephone number is (703) 305-3014.

Michail Belyavskyi, Ph.D.
Patent Examiner
Technology Center 1600
May 19, 2003


CHRISTINA CHAN
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600